No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: What Monday Brings?

hummmmmm,,,,,,,,,,,,,,,,,,,,""""KD wouldn't be pleased if shares of ZEN traded below $1"""""!!!!!!!!!!,,,,,,,,,,,,,,not sure if that is the case!!,,,,,,,,,,,,,I think we are flogging a dead horse with that assumption...............KD ,,if he wants to market these epigenetic drugs.....and it looks like he does,,then he dont give a rats derriere about present share price,,,,,,,,,,,,,I make the assumption that as long as he and HL can buy large portions of this cutting edge technology at or below a buck then he is very comfortable with a low share price,,,,,,,,,,,,,,if they were in the game to trade shares then yes,,,,,,,,,,,,but nope I dont drink the koolaid that KD or HL care about share price at this stage,,,,,,,,,,,,they are rubbing thier paws and salivating at the possibilities in the future and when a PP can be had by them,,,,,,they have a business model in mind I am certain,,,and it aint to sell shares,,its to gain as many shares as possible with the least amount of pain to their pocket books,,,,,,,,,,jmo

Share
New Message
Please login to post a reply